

# Financial Analysis of Selected Pharmaceutical Companies in Bangladesh

Md. Tofael Hossain Majumder (Corresponding Author)

Lecturer, Department of Accounting and Information Systems  
Comilla University, Comilla, Bangladesh.

Phone: +8801816436176, Email: tofael\_cou@yahoo.com

Mohammed Mizanur Rahman

Lecturer, School of Business and Economics  
Atish Dipankar University of Science and Technology,  
Dhaka, Bangladesh.

Phone: +8801814319485, Email: mizancu@yahoo.com

## Abstract

With the rapid growth of trade, commerce and industries, the numbers of publicly traded companies are considerably increasing in Bangladesh. Pharmaceutical is an important adjunct of industrialization in the country. But the net profit of this industry has decreased for the last few years. This paper attempted to review the financial performance of this industry, to test its strengths and weaknesses. This study is based on both primary and secondary data. The collected data have been tabulated, analyzed and interpreted with the help of different financial ratios, Multivariate Discriminate Analysis (MDA) as developed by Prof. Altman and statistical tools like mean, standard deviation (SD), coefficient of variance (CV) and T-test, etc. It was observed from the study of the financial statement of the Pharmaceutical industry that the profit earning capacity, liquidity position, financial position and the performance of the most of the Pharmaceuticals are not in sound position and it was also observed that the most of the Pharmaceuticals has a lower level position of bankruptcy. The reasons behind this position of the industry are inefficiency of financial management, absence of realistic goals, strict government regulation and increased cost of raw-materials, labor and overhead. The financial performance should be improved immediately. Therefore, the appropriate authority should take measures for the removal of the above problems.

**Keywords:** Financial Performance, Ratio Analysis, Pharmaceuticals Industry, Multivariate Discriminate Analysis (MDA), T-test.

## 1. Introduction

Financial analysis is the process of identifying the financial strengths and weaknesses of the firm by properly establishing relationship between the items of the balance sheet and the profit and loss account Pandey (1979). Financial Statements (income statement, cash flow statement, owners' equity statement and balance sheet) contain a wealth of information which, if properly analyzed and interpreted, can provide valuable insights into a firm's performance and position. Performance measurement of public enterprises has been the subject matter of discussion for planners, administrators, managers, economists and academics since long. But some lack of clarity about performance and the existence of defensive attitude on the part of those who have to take responsibility for inefficient operations have the effect of inhibiting both frame discussion and decisive action in this regard Bunnett (1987). Analysis of financial statements is of interest to lenders, security analysts, managers and others Prasanna (1995). Trade creditors are interested in the firm's ability to meet their claims. Their analysis will therefore, confine to the evaluation of the firm's liquidity position. The suppliers are concerned with the firm's solvency and survival. They analyze the firm's profitability over time. Long term creditors place more emphasis on the firm's solvency and

profitability. The investors are most concerned about the firm's earnings. So, they concentrate on the analysis of the firm's present and future profitability as well as earning ability and risk Abu Sina and Arshed Ali (1998). Publicly traded companies are the economic pulse of a nation. Their birth, prosperity and demise generally reflect the financial condition of the country. A fairly reliable index of an economy in its process of growth and development is the rate of growth and decline of publicly traded companies. With the rapid growth of trade, commerce and industries, the numbers of publicly traded companies are considerably increasing in Bangladesh. Pharmaceutical is an important adjunct of industrialization in the country. There are 20 listed Pharmaceutical Companies in Dhaka Stock Exchange and 16 listed in Chittagong Stock Exchange. Analyzing the Industrial Life Cycle, it has been found that all of the listed companies have just reached the middle stage. No company could reach the maturity stage. In a word, the Pharmaceutical industry of the country is just improving. It is well known that the Pharmaceuticals industry is one of the key to earning foreign currency. On the other hand, most of the internal demand for drugs is fulfilled by the domestic Pharmaceutical industry of the country. But this industry of Bangladesh depends on foreign country for raw-material and technology. Now the time to make the Pharmaceutical firms self sufficient for the betterment of the country. At this time, performance of manufacturing enterprise, like Pharmaceutical, needs to be measured and analyzed. But evaluation of performance is not a regular practice in the country. Against this backdrop this study is an attempt to evaluate performance of some selected Pharmaceuticals for the period under study.

## 2. Objectives of the study

The study is designed to achieve the following objectives:

- (i) To assess the financial performance of the selected Pharmaceuticals firms.
- (ii) To examine the financial state of affairs of the selected Pharmaceuticals firms.
- (iii) To test the financial strengths and weaknesses of selected Pharmaceuticals firms.
- (iv) To pinpoint the causes of poor financial performance and suggest some measures to overcome the problems.

## 3. Hypothesis

The research is based on following hypothesis.

H<sub>0</sub>: There is no significant difference between the industry mean and the individual firm's ratio.

H<sub>1</sub>: There is significant difference between the industry mean and the individual firm's ratio.

## 4. Methodology of the study

Data has been taken from a sample of 9 Pharmaceuticals in Bangladesh. For the study only A and B category Pharmaceuticals are considered. "A" category Pharmaceutical includes those Pharmaceuticals that hold annual general meeting (AGM) and declare minimum 10% dividend regularly. The trading time of "A" category Pharmaceutical's share is T+3. "B" category Pharmaceutical includes those Pharmaceuticals that hold annual general meeting (AGM) regularly but declare dividend at a rate below 10% on a regular basis. The trading time of "B" category Pharmaceutical's share is also T+3. "Z" category Pharmaceutical includes those Pharmaceuticals that neither hold annual general meeting (AGM) nor declare dividend on a regular basis. The trading time of "Z" category Pharmaceutical's share is T+7. Moreover, the size of the Pharmaceuticals, availability of information, and year of establishment are also considered for selecting the Pharmaceuticals. The study covers a three year period from 2005-06 to 2007-08. This study is based on both primary and secondary data. Secondary data are the annual reports of the selected Pharmaceuticals firms and various studies made available through library work. The primary data was collected through personal interview and discussions with the concerned executives of the selected Pharmaceuticals firms.

The collected data have been tabulated, analyzed and interpreted with the help of different financial ratios, Multivariate Discriminate Analysis (MDA) as developed by Prof. Altman and statistical tools like mean, standard deviation (SD), coefficient of variance (CV) and T- test, etc. The hypothesis has been tested statistically to arrive at conclusion and policy implication.

## 5. Literature Review

Financial ratios are the simplest tools for evaluating the financial performance of the firm Wen-Cheng LIN et. al (2005). One can employ financial ratios to determine a firm's liquidity, profitability, solvency, capital structure and

assets turnover. Hannan and Shaheed (1979) used financial ratios to show the financial position and performance analysis of Bangladesh Shilpa Bank. He showed that techniques of financial analysis can be used in the evaluation of financial position and performance of financial institution as well as non financial institutions even Development Financial Institutions (DFI). Altman (1968) used financial ratios to predict corporate bankruptcy. He found that the bankruptcy model has an accuracy rate of 93% and is very successful in predicting failed and non-failed firms. Sina and Arshed Ali (1998) used financial ratios to test the financial strengths and weaknesses of Khulna Newsprint Mills Ltd. He found that due to lack of planning and control of working capital, operational inefficiency, obsolete store, ineffective credit policy, increased cost of raw materials, labor and overhead, the position of the company was not good. Saleh Jahur and Mohi Uddin (1995) used financial ratios to measure operational performance of limited company. They used profitability, liquidity, activity and capital structure to measure operational performance. Saleh Jahur and Parveen (1996) used Altman's MDA model to conclude the bankruptcy position of Chittagong Steel Mills Ltd. They found that absences of realistic goals, strict govt. regulation are the main reasons for the lowest level of bankruptcy. Ohlson (1980) employed financial ratios to predict a firm's crisis. He found that there are four factors affecting a firm's vulnerability. These factors are the firm's scale, financial structure, performance and liquidity.

In the article "The Assessment of Financial and Operating Performance of the Cement Industry: A Case Study of Confidence Cement Limited", Dutta and Bhattacharjee (2001) found that the investment in cement was fairly profitable. Salauddin (2001) examined the profitability of the Pharmaceutical Companies of Bangladesh. By using ratio analysis, mean, standard deviation and co-efficient of variation he found that the profitability of the Pharmaceuticals sector was very satisfactory in terms of the standard norms of return on investment. Hye & Rahman (1997) conducted a research to assess the performance of the selected private sector general insurance companies in Bangladesh. The study revealed that the private sector insurance companies had made substantial progress. The study found that the insurance companies were keeping their surplus funds in the form of fixed deposits with different commercial banks due to absence of suitable avenues for investment. These studies attest that the ratio analysis and MDA are the good method to evaluate firm performance. The researcher uses these tools to measure the financial performance of 9 selected Pharmaceutical firms in this paper.

## **6. Theoretical discussion of Financial Ratio**

Financial analysis offers a system of appraisal and evaluation of a firm's performance and operations; it is the analysis of the financial statement of an enterprise. The analysis of financial statement can be best done by various yardsticks of which, the important is known as ratio or percentage analysis. Ratio is a numerical or an arithmetical relation between two figures. It is expressed when one figure is divided by another. Accounting ratios show inter-relationship which exist among various accounting data. Accounting ratio can be expressed in various ways such as, a pure ratio, a rate or a percentage. Ratio analysis is certainly a very admirable device because it is simple and it has a predictive value. Management and other users thus, rely substantially on the financial ratios based on accounting data for making assessments and predictions of past performance, present position and probable future potentials. One important way for diagnosing the financial health is to measure the profitability, liquidity, activity and solvency and the level of the bankruptcy of enterprise.

### *6.1 Profitability Ratio*

Profitability is a measure of efficiency. It also indicates public acceptance of the product and shows that the firm can produce competitively. The profitability ratios measure the performance of profit of an enterprise. In other words the profitability ratios are designed to provide answers to questions such as what is the rate of profit?. What is EPS? What is the rate of investment? What is the rate of equity? Is the profit earned by the enterprise adequate? What is the dividend payout ratio? What is retention ratio and so on? The analysis of the profitability ratio is important for the shareholders, creditors, prospective investors, bankers and the government alike. Gross profit margin ratio, return on investment, net profit margin ratio and operating profit ratio can be used to measure the liquidity position of the enterprise.

### *6.2 Liquidity Ratio*

The liquidity ratios measure the ability of an enterprise to meet its short-term obligations and reflect the short-term financial strength of an enterprise. Liquidity is a pre-requisite for the very survival of an enterprise. Analysis of liquidity is very important in knowing the liquidity status, movement of funds, idle fund (if any) which will not only help financial management to keep the liquidity position of the company in order but also make sure of payment to short-term creditors, interested in short-term solvency of the company. Liquidity ratios reveal the rate at which fixed

and working assets are being converted into cash and the time when the cash will be required. Current ratio, quick ratio and working capital to total asset ratio can be used to measure the liquidity position of the enterprise.

### 6.3 Activity Ratio

Activity ratios indicate the effectiveness of an enterprise with which different assets are managed and utilized in a business. The efficiency in assets management is measured by activity ratio which involves the comparisons between the level of sales and investment in various assets accounts, inventories, bill receivable, fixed assets and others. The activity can be measured by the use of activity ratios such as inventory turnover, fixed assets turnover and total assets turnover.

### 6.4 Solvency Ratio

The long-term solvency of a company is an important aspect to the present and future long-term creditors, banks, debenture holders etc. Before sanctioning loan or buying a debenture or preference share, they are interested to see whether the company has ability to pay the interest regularly as well as repay the installment of the principal on due date or in one lump sum at the time of maturity. The long-run solvency of a company can be measured by the use of solvency ratios named debt to total assets, the time interest earned and retained earning to total assets.

## 7. Findings and Discussions

### 7.1 Profitability Ratio

The tables (01, 02,03,04,05 and 06) depict various financial ratios covering profitability of the selected Pharmaceuticals for the period under study.

#### 7.1.1 Gross Profit Margin

The earnings in terms of sales can be assessed through the profit margin. The gross profit margin reflects the effectiveness of pricing policy and of production efficiency. Some authors consider that a profit margin ratio ranging from 20% to 30% has been considered as the standard norm for any industrial enterprise. The table-01 shows that BXPHARMA he highest average gross profit ratio over the study period. The average gross profit ratios range from highest 34.43% in BXPHARMA to lowest 9.42% in BEACONPHAR study is to found that the industry average gross profit ratio was 17.69% and the average gross profit ratio of all but five samples was below industry average. The co-efficient of variation of gross profit ratios of the samples reveals that the variation of gross profit over the years is negligible except two sample companies (SQURPHARMA and BXPHARMA) which speaks about the stability of gross profit earning of this sector. In view of standard, the gross profit margin of SQURPHARMA , IBNSINA, BXPHARMA, AMBEEPHA during the period was higher than standard norm and shown an increasing trend but the ratio for ACTIVEFINE, RENETA, BEACONPHAR, BXPHARMA , and PHARMAID was lower than the standard. The higher ratio indicates favorable purchasing and markup policies and the ability of management to develop sales volume and lower ratio indicates unfavorable purchasing and markup policies and the inability of management to develop sales volume. This ratio also indicates that the selected enterprise (SQURPHARMA, IBNSINA, BXPHARMA, and AMBEEPHA) seems to be in an advantage position to service in the face of falling sales prices, rising cost of production or decline demand for the product. From the calculated value of t it is seen that there is a significant difference in gross profit ratio between industry average and individual pharmaceuticals firms except SQURPHARMA and AMBEEPHA.

#### 7.1.2 Net Profit Margin

The ratio reveals the overall profitability of the concern, that's why it is very useful to the proprietors and prospective investors. It also indicates management efficiency in manufacturing, administrating and selling of the products. The table-02 shows that the net profit ratios range from highest 10.75% in SQURPHARMA to lowest 13.36 % ( negative) in BXPHARMA. SQURPHARMA earned the highest average net profit margin (10.75%) and industry average is 1.35%. The calculated ratios in table-02 are all very lower position except SQURPHARMA, IBNSINA, RENETA and PHARMAID. Lower position refers to the company's failure to achieve satisfactory return on owners' equity. It also indicates that the efficiency of the samples is very low in position. The position of BXPHARMA is negative. The co-efficient of variation of net profit ratios of the samples reveals that the variation of net profit over the years is negligible except two sample companies SQURPHARMA (and BXPHARMA) which speaks about the stability of net profit earning of this sector. Calculated values of t' state that there is a significant difference in net profit ratio between industry average and 5 individual pharmaceuticals firms (IBNSINA, BXPHARMA, RENETA, BEACONPHAR and PHARMAID).

### 7.1.3 Return on Investment (ROI)

This ratio measures the profitability of enterprise on total investment. The Planning Commission, Government of Bangladesh has declared that the entire existing project in the public sector would have to guarantee a fixed return to 7.5% of the investment. This may be considered as the standard norm for the industrial enterprise. The table-03 shows that the return on investment on an average for the period under study varies from maximum 19.48% in SQRPHARMA to minimum 0.70% in BPL and the industry average is 6.67% which is lower than the standard norm of 7.5%. The ratio for BXPHERMA is negative. It is seen from the table that ACTIVEFINE, BXPHERMA, RENETA, BEACONPHAR, PHARMAID and BPL have a low ratio as compared to the industry average and standard norm, which is indicative of poor earning in terms of investment, the return on investment for SQRPHARMA(24.38%), IBNSINA (14.39%) and AMBEEPHA (11.16%) should be considered as extremely satisfactory as they are more than the industry average ratio and as well as the standard norm and this ratios are indicative of very good profitability in terms of investment. ACTIVEFINE, BXPHERMA, RENETA, BEACONPHAR, PHARMAID and BPL show a declining trend which indicates the inefficiency of the business as a whole. The co-efficient of variation of return on investment ratios of the samples reveals that the variation of return on investment over the years is negligible except two sample companies (SQRPHARMA and AMBEEPHA) which speaks about the stability of return on investment of this sector. From the calculated value of t it is observed that there is a significant difference in return on investment between industry average and 4 individual pharmaceuticals firms (ACTIVEFINE, IBNSINA, PHARMAID and BPL). For other pharmaceuticals the difference is insignificant.

### 7.1.4 Operating Profit Ratio

Operating Profit refers to the profit of an enterprise, which is obtained after deducting all operating expenses from gross profit. This ratio establishes the relationship between operating profit and sales. The ratio indicates the portion remaining out of every taka worth of sales after all operating cost and expenses have been met. It represents the overall earnings of an enterprise and one can get a clear idea about the efficiency of an enterprise from its operating profit ratio. The higher the ratio, the better is the overall efficiency of the enterprise. Operating profit ratio ranging 4% to 6% is considered norm for the purpose of comparison and control by some authors (Jain and Narang, Jahur, Hye). The table-04 shows that the average operating profit ratio of the sample pharmaceuticals ranges from highest 29.02% in BXPHERMA to lowest 0.41% in BEACONPHAR. The industry average operating profit ratio is 10.72% and most of the companies (5 out of 9) failed to attain the average but most of the companies'(5 out of 9) operating profit ratio is more than standard. As to variation of operating profit over the years, it is revealed by the coefficient of variance that the variation ranges from 0.033% in BEACONPHAR to 29.259% in BXPHERMA. The coefficient of variance of 10.407% and 29.259% indicates inconsistency in the overall earnings of SQRPHARMA and BXPHERMA. The negligible variation of 0.631% in ACTIVEFINE, 2.126% in IBNSINA, 1.659% in RENETA, 0.033% in BEACONPHAR, 3.553% in AMBEEPHA, 0.130% in PHARMAID and 0.520% in BPL indicate extremely desirable stability position. From the calculated value of t it is observed that there is a significant difference in operating profit ratio between industry average and almost all individual pharmaceuticals firms except SQRPHARMA.

### 7.1.5 Return on Capital Employed

The most independent ratio for assessment of profitability is the return on capital employed. It reflects the overall efficiency with which capital is used. Here, Capital Employed=Equity share capital + Preference share capital+ Undistributed profit+ Reserve and Surplus+ Long term Liabilities- Fictitious Assets. A rate of return ranging from 11% to 12% on Capital employed may be considered as reasonable for a selected enterprise. The table-05 represents the return on capital employed ratio of the sample pharmaceuticals for the study period. The table shows that the average returns on capital employed ranges from 1.46% in BPL to 13.79% in SQRPHARMA and the average ratio is negative for BXPHERMA (-7.52%). It appears from the table that the industry average return on capital employed is 3.59% which is not satisfactory in terms of the standard norm. It is seen from the table that only SQRPHARMA has a high ratio as compared with standard norm, IBNSINA, BEACONPHAR, AMBEEPHA and PHARMAID have a high ratio as compared to industry average. ACTIVEFINE, BXPHERMA, RENETA and BPL have a ratio lower than industry average, which is indicative of poor earning in terms of capital employed. It appears from the table that BXPHERMA has the highest variation (43.107%) and AMBEEPHA has the second highest variation (27.971%) as indicated by the coefficient of variation which indicates extremely instability in their earnings. The variation of this ratio for ACTIVEFINE (0.046%), SQRPHARMA (7.491%), IBNSINA (0.946%),



RENETA (4.113%), BEACONPHAR (2.369%), PHARMAID (0.575%) and BPL (0.033%) should be considered satisfactory. The lower ratios conclude that management should be more efficient in using the long term fund of owners and creditors. From the calculated value of  $t$  it is observed that there is a significant difference in return on capital employed between industry average and 4 individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, BXPHARMA and BPL). For other pharmaceuticals the difference is insignificant.

#### 7.1.6 Return on Total Assets

This ratio is calculated to measure the profit after the tax against the amount invested in total assets to ascertain whether assets are being utilized properly or not. Some authors consider 10% to 12% rate of return on total assets as reasonable norm for a profitable firms and this may be considered as reasonable norm for the selected enterprises. Table -06 shows that the average return on total assets ranges from 0.59% in BPL to 7.42% in SQURPHARMA and the average return on total assets for BXPHARMA is negative (-3.77%). It is seen from the table that the average return on total assets is 1.83% which is far away from standard norm. The average returns on total assets of all pharmaceuticals are below the standard norm which cannot be considered as satisfactory and desirable. The average return on total assets of BEACONPHAR (0.70%), BXPHARMA (-3.77%), AMBEEPHA (1.28%) and BPL (0.59%) are below the industry average. The calculated ratios show a decreasing trend for most of the pharmaceuticals during the period of study and lower ratios indicate the assets were not being utilized properly during the period. In the context of variation of this ratio over the years, it is found that the variation is almost stable. The calculated values of  $t$  state that there is a significant difference in return on total assets between industry average and 4 individual pharmaceuticals firms (SQURPHARMA, BEACONPHAR, PHARMAID and BPL). For other pharmaceuticals the difference is insignificant.

#### 7.2 Liquidity Ratio

The Current Ratio and Quick Ratio, Current Assets to Fixed Assets and Net Working Capital to Total Assets are used to assess liquidity position of an enterprise. The tables (07, 08, 09, and 10) depict various financial ratios covering liquidity of the selected pharmaceuticals for the period under study.

##### 7.2.1 Current Ratio

This ratio is a measure of the firm's short term solvency of the firm's liquidity. It indicates the ability of the company to meet its current obligations. If the current ratio is too low, the firm may have difficulty in meeting short run commitment as they measure. If the ratio is too high the firm may have an excessive investment in current assets or be under utilizing short term credit. Some authors consider 2:1 as standard norm for current ratio. Table-07 shows that the industry average current ratio is 0.94:1 which indicates that the industry is not able to meet its current obligations from its current assets. The average current ratio ranges from 0.57:1 in AMBEEPHA to 1.12:1 in SQURPHARMA. The average current ratios of BEACONPHAR (0.61:1), AMBEEPHA (0.57:1) and BPL (0.85:1) are below the industry average as well as below the standard norm. The average current ratios of ACTIVEFINE (1.08:1), SQURPHARMA (1.12:1), IBNSINA (1.10:1), BXPHARMA (1.06:1), RENETA (1.08:1) and PHARMAID (0.98:1) are above the industry average but below the standard norm. It is seen from the table that all these ratios are far from standard norm. Therefore it can be said that the liquidity in terms of current ratio had been quite inadequate in all the years under study for all the pharmaceuticals. The downward trend of current ratios of BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL indicate the inefficient liquidity management in case of the selected pharmaceuticals, the financial position is very unsatisfactory and the companies' short term solvency is threatened. From the coefficient of variation it is clear that the variation of current ratio over time is negligible. From the calculated value of  $t$  it is seen that there is a significant difference in current ratio between industry average and 4 individual pharmaceuticals firms (RENETA, BEACONPHAR, AMBEEPHA, and PHARMAID). For other pharmaceuticals the difference is insignificant.

##### 7.2.2 Liquid (Quick or Acid Test) Ratio

It measures the firm's ability to meet short term obligations from its most liquid assets. Table-08 shows that the industry average of liquid ratio is 0.57:1 which is very lower than the standard (1:1) ratio. The table reveals that the average liquid ratio ranges from 0.29:1 in IBNSINA and in BEACONPHAR to 1.28:1 in ACTIVEFINE. The average liquid ratios of IBNSINA (0.29:1), RENETA (0.55:1), BEACONPHAR (0.29:1), AMBEEPHA (0.38:1) and BPL (0.43:1) are below the industry average as well as far away from standard norm and the average ratios of SQURPHARMA (0.64:1), BXPHARMA (0.59:1), and PHARMAID (0.70:1) are above the industry average but below the standard norm. It indicates that all pharmaceuticals except ACTIVEFINE (average liquid ratio is 1.28:1)

are financially very weak and have no ability to pay its most immediate liabilities. It is also observed that this position is declining for most of the pharmaceuticals and it is the dangerous signal for the companies. In the context of variation of this ratio over the years, it is found that the variation is almost stable. From the calculated value of  $t$  it is observed that there is a significant difference in liquid ratio between industry average and 4 individual pharmaceuticals firms (ACTIVEFINE, IBNSINA, BEACONPHAR and AMBEEPHA). For other pharmaceuticals the difference is insignificant.

### 7.2.3 Current Assets to Fixed Assets

Another criterion for liquidity assessment is the ratio between current assets to fixed assets. This ratio will differ from industry to industry and, therefore, no standard can be laid down. A decrease in ratio may mean that trading is slack or more mechanization has been put through. The table-09 shows that the industry average current asset to fixed assets is 0.78:1. It is seen from the table that the average current assets to fixed assets ratio ranges from 0.40:1 in ACTIVEFINE to 1.06:1 in SQRPHARMA and the average ratio for ACTIVEFINE (0.40:1), IBNSINA (0.79:1), RENETA (0.51:1), BPL (0.61:1) is lower than industry average and the average ratio for SQRPHARMA (1.06:1), BXPBARMA(0.94:1), BEACONPHAR (0.89:1), AMBEEPHA (0.92:1) and PHARMAID (0.93:1) is higher than the industry average. The calculated ratios show a decreasing trend for some pharmaceuticals which mean that trading is slack or more mechanization has been put through in that pharmaceuticals. From the coefficient of variation it is clear that the variation of current ratio over time is negligible. From the calculated value of  $t$  it is observed that there is a significant difference in current assets to fixed assets between industry average and ACTIVEFINE. For all other pharmaceuticals the difference is insignificant.

### 7.2.4 Net Working Capital to Total Assets

Table-10 shows net working capital to total assets ratios for the selected pharmaceuticals for the study period. It is seen from the table that the industry average of net working capital to total assets ratio is -0.099:1. The table reveals that the average net working capital to total assets ratios of ACTIVEFINE (0.0383), SQRPHARMA (0.0543), IBNSINA (0.0403), BXPBARMA (0.0247), RENETA (0.0247) and BPL (0.0407) are higher than industry average and the average ratio of BEACONPHAR (-0.2960), AMBEEPHA (-0.0004), PHARMAID (-0.0114), are lower than industry average and the figures are negative. From the calculated ratios it is clearly seen that the net working capital to total assets ratios are very small and for three pharmaceuticals the ratio is negative. Such state of affairs indicates the inability and inadequacy of net working capital to cover the total assets of the selected enterprise for the period under review. From the coefficient of variation it is seen that the variation of net working capital to total assets is insignificant. From the value of  $t$  it is observed that there is a significant difference in net working capital to total assets between industry average and 3 individual pharmaceuticals firms (RENETA, BEACONPHAR and AMBEEPHA). For other pharmaceuticals the difference is insignificant.

## 7.3 Activity Ratios

Activity ratios show the intensity with which the firm uses its assets in generation sales. These ratios indicate whether the firm's investments in current and long-term assets are too small or too large. The objective is to have "enough" assets but not "too many". The tables (11, 12, and 13) depict various activity ratios of the selected pharmaceuticals for the period under study.

### 7.3.1 Inventory Turnover Ratio

This ratio is also known as stock turnover ratio, establishes relationship between sales (or cost of goods sold) and the total inventory (or average inventory). A low inventory turnover may indicate an excessive investment in inventories a high ratio often means that the firm is running out of stock, resulting in poor service to customers. It assists the financial manager in evaluating inventory policy to avoid any danger of over stocking as a prelude to the effective utilization of the resources of the firm. Higher the ratio the better it is because it shows that stock is rapidly turned over. The table-11 shows that the industry average inventory turnover is 6.45 times. It is seen from the table that the average inventory turnover ratio ranges from 1.47 times in BXPBARMA to 19.99 times in ACTIVEFINE. Some authors consider 8 to 9 times of inventory turnover ratio as the reasonable norm for an efficient concern. From the study it is seen that the average inventory turnover for all selected pharmaceuticals except three pharmaceuticals, ACTIVEFINE(19.99 times), BEACONPHAR (9.52), PHARMAID (8.13), is lower than the industry average as well as standard norm which implies excessive inventory levels or a slow moving or obsolete inventories. If it is the obsolete inventories then it has to be written off. This will adversely affect the working capital and liquidity position of the firm. The calculated ratios indicate that the sale management of the selected pharmaceuticals can't be said to

be efficient to sell its product. As to variation of inventory turnover over the years, it is revealed by the coefficient of variance that the coefficient of variance of 17.692% indicates inconsistency in the inventory turnover of BEACONPHAR. The negligible variation of 0.675% in SQRPHARMA, 0.079% in IBNSINA, 0.086% in BXPCHARMA, 2.141% in RENETA, 1.012% in AMBEEPHA, 5.889% in PHARMAID and 1.706% in BPL indicate extremely desirable stability position and with a variation of 8.689% in ACTIVEFINE shows a rather satisfactory stability position. The values of t state that there is a significant difference in inventory turnover between industry average and 4 individual pharmaceuticals firms (ACTIVEFINE, SQRPHARMA, IBNSINA and BXPCHARMA). For other pharmaceuticals the difference is insignificant.

### 7.3.2 Net Fixed Assets Turnover

The ratio indicates the extent of generating sales volume in terms of net fixed assets. Some authors consider that an ideal fixed assets turnover for an enterprise should be 5 times of net fixed assets and hence this may also be considered so far over selected case. Table-12 shows the net fixed assets turnover ratios for the selected pharmaceuticals for the study period. From the calculated ratios it is seen that the industry average net fixed assets turnover is 1.67 which is far away from the standard. The average ratio ranges from 0.58 times in BXPCHARMA to 4.41 times in BPL. The average ratio of ACTIVEFINE (1.17times), SQRPHARMA (1.41times), IBNSINA (1.16 times), BXPCHARMA (0.58times), RENETA (0.94 times) and AMBEEPHA (1.45 times) is lower than industry average as well as very lower than standard. Only three pharmaceuticals, BEACONPHAR (3.87 times), PHARMAID (2.02 times), BPL (4.41 times), have average ratio more than industry average but lower than standard. This low level of ratio indicates poor sales volume in terms of fixed assets. This indicates an inefficient use of fixed capital. From the coefficient of variation it is clear that the variations are very insignificant. From the calculated value of t it is observed that there is a significant difference in net fixed assets turnover between industry average and 5 individual pharmaceuticals firms (ACTIVEFINE, IBNSINA, BXPCHARMA, RENETA and BEACONPHAR). For SQRPHARMA, AMBEEPHA, PHARMAID and BPL the difference is insignificant.

### 7.3.3 Total Assets Turnover

Another activity ratio is total assets turnover. This is a measure of the extent of generating sales in terms of the total assets. A standard norm of 200% (i.e. 2 times) of this ratio is considered norm by some authors for an industrial enterprise. This may also be taken as such for our selected pharmaceuticals. Table-13 reveals that the average total assets turnover ratio ranges from 0.30 times in BXPCHARMA to 2.04 times in BEACONPHAR and the industry average is 0.90 times which is very lower than standard norm. It is seen from the table that the average ratio of ACTIVEFINE (0.81 times), SQRPHARMA (0.69 times), IBNSINA (0.65 times), BXPCHARMA (0.30 times), RENETA (0.62 times) and AMBEEPHA (0.77 times) is lower than the industry average as well as standard norm, but the average ratio of BEACONPHAR (2.04 times) is higher than industry average as well as standard norm and the average ratio of PHARMAID (1.00 time), BPL (1.24 times) is higher than the industry average but lower than standard norm. Such a low level of total assets turnover ratio of ACTIVEFINE, SQRPHARMA, IBNSINA, BXPCHARMA, RENETA and AMBEEPHA indicates that the selected pharmaceuticals (ACTIVEFINE, SQRPHARMA, IBNSINA, BXPCHARMA, RENETA, AMBEEPHA, PHARMAID and BPL) generate lower taka of sales per taka of tangible assets which may be an indication of poor use of fixed and circulating capital. On the other hand the position is strong for BXPCHARMA, BEACONPHAR. From the coefficient of variation it is seen that the variation over time is stable. From the calculated value of t it is observed that there is a significant difference in total assets turnover between industry average and 5 individual pharmaceuticals firms (SQRPHARMA, IBNSINA, BXPCHARMA, RENETA and BEACONPHAR). For other pharmaceuticals the difference is insignificant.

## 7.4 Solvency Ratios

Debt-Equity ratio and Debt to Total Assets ratio are commonly used solvency ratios. The tables (14 and 15) depict various solvency ratios of the selected pharmaceuticals for the period under study.

### 7.4.1 Debt-Equity Ratio

Equity represents a “cushion” for share-holders. This is a ratio calculated to measure the relative proportions of outsiders’ funds and shareholder’ funds invested in the company. This ratio is also known as external-internal equity ratio. The standard ratio is 2:1. The table-14 shows the debt-equity ratio for the selected pharmaceuticals for the study period. It is revealed from the table that the average debt-equity ratio is 2.01:1. The debt-equity ratio ranges from 0.33:1 in ACTIVEFINE to 7.28:1 in AMBEEPHA. It is seen from the table that the average ratio of ACTIVEFINE (0.33:1), SQRPHARMA (1.08:1), IBNSINA (0.65:1), RENETA (1.24:1) and BPL (0.65:1) is lower



than the industry average as well as standard norm, but the average ratio of BXPHERMA (2.27:1), BEACONPHAR (3.19:1), AMBEEPHA (6.23:1) and PHARMAID (2.44:1) is higher than the industry average as well as standard norm. These low levels of debt-equity ratio of ACTIVEFINE, SQURPHARMA, IBNSINA, RENETA and BPL mean that the claims of creditors are lower than those of owners and the company has not liberally used debt to finance its assets. It indicates an inefficient financial management. On the other hand the position is strong for BXPHERMA, BEACONPHAR, AMBEEPHA and PHARMAID. From the coefficient of variance it is seen that the variations of ACTIVEFINE(0.001:1), SQURPHARMA(0.019:1), IBNSINA(0.007:1), BXPHERMA(0.047:1), RENETA(0.008:1), BEACONPHAR(0.241:1), AMBEEPHA(0.057:1), PHARMAID(0.063:1) and BPL(0.091:1) are very insignificant i.e. the variation is stable. From the calculated value of t it is seen that there is a significant difference in debt-equity ratio between industry average and 7 individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, IBNSINA, RENETA, BEACONPHAR, AMBEEPHA and BPL). For other pharmaceuticals (BXPHERMA and PHARMAID) the difference is insignificant.

#### 7.4.2 Debt to Total Assets Ratio

The objective of this ratio is to assign what portion of total assets (debt + equity) is collected from debt. Some authors consider that debt to total assets ratio should be 50% for an industrial enterprise. The table-15 shows the debt to total assets ratio for the selected pharmaceuticals for the study period. It is observed from the table that the industry average debt equity ratio is 36% which is lower than the standard norm. It is also seen from the table that the average ratio ranges from 7% in ACTIVEFINE to 83% in AMBEEPHA. The calculated ratios indicate the claim of creditors is about very small in percentage to the shareholders of ACTIVEFINE (7%), SQURPHARMA (28%), IBNSINA (35%), RENETA (33%), and BEACONPHAR (24%), PHARMAID (27%) and BPL (13%) Such a lower ratio of debts to total assets of selected pharmaceuticals reveals the fact that they are less dependent on debt rather than on their own capital for financing their projects. On the other hand the average ratio of BXPHERMA (75%) and AMBEEPHA (83%) is higher than the average as well as the standard norm which indicates that BXPHERMA and AMBEEPHA are more dependent on debt rather than their own capital for financing project. From the coefficient of variation it is clear that the variation over time is very insignificant for all the selected pharmaceuticals. From the calculated value of t it is observed that there is a significant difference in debt to total assets between industry average and 6 individual pharmaceuticals firms (ACTIVEFINE, BXPHERMA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL). For other pharmaceuticals the difference is insignificant.

### 8. Testing financial soundness of sample Industry

After examining liquidity, profitability and solvency of sample Industry, now it is necessary to examine the overall financial soundness of the selected pharmaceuticals during the study period. In this context Multivariate Discriminate Analysis (MDA) model as developed by Prof. Altman may be considered worth while. The said model can give some rough idea about the financial soundness of the selected industry. He developed the following equation for judging the financial soundness of an enterprise.

$$Z = 0.012x_1 + 0.014x_2 + 0.033x_3 + 0.006x_4 + 0.999x_5$$

Where;

X<sub>1</sub>: Working Capital / Total Assets

X<sub>2</sub>: Retained earnings / Total Assets

X<sub>3</sub>: Earning before interest & taxes / Total Assets

X<sub>4</sub>: Market value of equity / Total debt

X<sub>5</sub>: Sales / Total Assets

Z: Overall index

In order to test the overall financial soundness of the selected pharmaceuticals, it needs to calculate the ratios of working capital to total assets, retained earnings to total assets, earning before interest & taxes to total assets, market value of equity to book value of total debt and sales to total assets.

The table-16 depicts the year wise as well as average position of the ratios of working capital to total assets, retained earnings to total assets, earning before interest and taxes to total assets, market value of equity to total debt and sales to total assets.

The year wise position of all these ratios excepting market value of equity to total debt had been either negative or to low positive. These resulted in poor financial performance of the sample pharmaceuticals during study period. It is seen from the table that the average positions of the working capital to total assets are 0.058, 0.174, 0.04, 0.021, 0.025, (0.296), (0.0004), (0.012), (0.079) times, the retained earnings to total assets ratios are 0.012, 0.074, 0.007, (0.0370), (0.032), (0.344), 0.0103, 0.0045, 0.005 times, the earning before interest & taxes to total assets are 0.022, 0.115, 0.092, 0.045, 0.156, 0.052, 0.123, 0.059, 0.024 times, the sales to total assets are 0.813, 0.687, 0.647, 0.299, 0.62, 2.04, 0.749, 1.00, 1.227 times for ACTIVEFINE , SQURPHAEMA , IBNSINA, BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL respectively. Such lower positions of these ratios indicate very unsatisfactory position. On the other hand the average market value of equity to total debt are 3.072, 0.94, 1.547, 0.443, 0.813, 0.32, 0.138, 0.414, 1.767 times for ACTIVEFINE , SQURPHARMA , IBNSINA, BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL respectively which indicate unsatisfactory position of financial performance of the sample industry. From coefficient of variance it is clear that the variance over time is very insignificant for all the pharmaceuticals.

The Table-17 shows the year-wise as well as average position of Z's score of the sample pharmaceuticals during the study period. After putting the respective average values of  $x_1$ ,  $x_2$ ,  $x_3$ ,  $x_4$  and  $x_5$ , in the aforesaid equations as developed by Prof. Altman, Z score was estimated. The average Z score ranges from 0.298 in BXPHARMA to 2.033 in BEACONPHAR and the industry average Z score is 0.909 comparing with Prof. Altman's conclusion that firms with Z score above 2.99 were solvent while those below Z score of 1.81 were bankrupt.

Average Z score of sample pharmaceutical ACTIVEFINE (0.832), SQURPHARMA (0.735), IBNSINA (0.655), BXPHARMA (0.298), RENETA (0.633), AMBEEPHA (0.754) are lower than the industry average as well as the range provided by Prof. Altman. On the other hand average Z score of sample pharmaceuticals of PHARMAID (1.004) and BPL (1.243) are higher than the industry average but lower than the range provided by Prof. Altman. Only Z score of BEACONPHAR (2.033) exists within the range provided by Prof. Altman. The table shows the position of bankruptcy at a lower level during the period for all the selected pharmaceuticals except BEACONPHAR.

It can be concluded that the overall financial soundness of the sample Industry during the study period had been worst leading to total bankruptcy of the industry. From the calculated value of t it is observed that there is a significant difference in Z score between industry average and 6 individual pharmaceuticals firms (SQURPHARMA, IBNSINA, BXPHARMA, RENETA, BEACONPHAR and AMBEEPHA). For other pharmaceuticals the difference is insignificant.

## 9. Conclusions

From the discussion it can be concluded that the financial position and operational performance of the most of the selected pharmaceuticals were not satisfactory. The inefficiency of financial management may be a major cause for such a poor position of the state of affairs. This view was also substantiated by using Prof. Altman's MDA model. By applying this model it is seen that the overall financial position of the sample pharmaceuticals was at the lower level of bankruptcy except only one pharmaceuticals (BEACONPHAR). The main reasons attributed to such a situation were reported to be poor market demands, scarcity of raw materials, high competition, vanished quota system, management in attention, lack of realistic goals, strict government regulations, political instability, increased price of raw materials and others, adverse environmental factors etc. In order to save the pharmaceuticals from total bankruptcy the financial performance of the sample pharmaceuticals should be improved as early as possible.

The followings are the recommendation from the researcher:

- i. The financial management specially purchase, sales and inventory management have to be motivated, so that they act all the tasks cordially, efficiently and honestly.
- ii. The Pharmaceuticals should regularly make use of ratio analysis and measure should be taken to improve undesirable ratios at least as to the point of industry's average.
- iii. Qualified, trained and experienced management personnel should be appointed.
- iv. Government regulations should be flexible and policy should be realistic.
- v. Operational efficiency should be increased by reducing cost and wastage and improving operating and management performance. Supply of working capital should be adequate.

- vi. Liquidity position of the selected Pharmaceuticals should be improved by reducing current liabilities.
- vii. Realistic goal should be set out.
- viii. A reasonable credit policy should be implemented, so that the main portion of profit does not spend in payment of fixed charges.
- ix. Accountability and motivation for achievement of performance and penalization for non-achievement of the same should be fixed up.

### References

- A.H.M. Bunnet. (1987). "Performance Evaluation of Public Enterprises in Bangladesh", *Journal of Business Administration*, Vol.13, No.1, p. 1
- Altman, E.I. (1968). "Financial Ratios, Discriminate Analysis and the Prediction of Corporate Bankruptcy", *The Journal of Finance*, Vol.4, pp. 589-609
- A. Salauddin. (2001). "Profitability of Pharmaceutical companies of Bangladesh". *The Chittagong University Journal of Commerce*, Volume 16, pp. 54-64
- D. D. Kanti Dutta & D. M. Kumar Bhattacharjee. (2001). "The assessment of financial and operating performance of the cement industry: A case study of confidence cement ltd." *The Chittagong University Journal of Commerce*, volume 16, pp. 1-16
- D.M.A.Hye & M.A. Rahman. (1997). "Performance of Selected Private Sector General Insurance Companies in Bangladesh", *Chittagong University Studies (Commerce)*, Vol. 13, pp. 137-160
- Dr. Md. Abdul Hannan Shaikh, & Muhammad Abdus Shaheed Miah. (1979). "Financial Position and Performance analysis of Bangladesh Shilpa Bank", *Islamic University Studies (part C)*, Vol. 1, No. 2, December p. 207-225.
- I.M. Pandey. (1979). *Financial Management*, Vikas Publishing House Pvt. Ltd, New Delhi, pp. 109-116.
- J.A. Ohlson. (1980). "Financial Ratios and the Probabilistic Prediction of Bankruptcy", *Journal of Accounting Research*, Vol.19, No. 1, pp. 61-80
- Md. Abu Sina & Md. Arshed Ali Matubber. (1998). "Financial Statement Analysis of Khulna Newsprint Mills Ltd.", *Islamic University Studies (part C)*, Vol. 1, No. 2, December, pp179-189.
- Mohammad Saleh Jahur & Mohammad Mohi Uddin. (1995). "Measurement of operational performance through ratio analysis – A case study of Usmania Glass Sheet Factory Ltd. Chittagong", *Chittagong University Studies (Commerce)*, vol XI, pp. 245-255
- Mohammad Saleh Jahur & Jannat Ara Parveen. (1996). "An analysis of financial performance of public enterprises- A case study of Chittagong Steel Mills Ltd.", *Chittagong University Studies (Commerce)*, Vol. 12, pp. 173-184
- Prasanna Chandra. (1995). *The Investment Game*, New Delhi, Mc Graw Hill Publishing Co. Ltd. p.172
- S.P. Jain & K.L Narang,. *Financial Accounting*, Kalyani Publishers, Ludhiana, New Delhi, pp V1/27 – V1/44.
- Wen-Cheng LIN, Chin-Feng LIU and Ching-Wu CHU, (2005). "Performance efficiency evaluation of the Taiwan's shipping Industry: An application of DEA", *Proceeding of the Transportation Studies*, Vol.5, pp. 467-476

**Table-01: Gross Profit Margin**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean  | Industry Mean | S.D    | C.V    | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|-------|---------------|--------|--------|-----------|----------------|
| ACTIVEFINE                  | 11      | 13.56   | 13.51   | 12.69 | 17.69         | 1.4638 | 2.143  | -5.192*   | 0.027          |
| SQURPHARMA                  | 22.13   | 22.84   | 16.87   | 20.61 | 17.69         | 3.2612 | 10.635 | 1.553     | 0.261          |
| IBNSINA                     | 21.98   | 21.46   | 19.89   | 21.11 | 17.69         | 1.0881 | 1.184  | 5.444*    | 0.032          |
| BXPBARMA                    | 39.03   | 29.18   | 35.08   | 34.43 | 17.69         | 4.9571 | 24.573 | 5.849*    | 0.028          |
| RENETA                      | 9.62    | 10.12   | 11.82   | 10.52 | 17.69         | 1.1533 | 1.330  | -10.768** | 0.009          |
| BEACONPHAR                  | 9.70    | 9.28    | 9.27    | 9.42  | 17.69         | 0.2454 | 0.060  | -58.388** | 0.000          |
| BEACONPHAR                  | 18.44   | 19.90   | 22.57   | 20.30 | 17.69         | 2.0943 | 4.386  | 2.161     | 0.163          |

|          |       |       |       |       |       |        |       |           |       |
|----------|-------|-------|-------|-------|-------|--------|-------|-----------|-------|
| PHARMAID | 14.16 | 14.25 | 14.32 | 14.24 | 17.69 | 0.0802 | 0.006 | -74.429** | 0.000 |
| BPL      | 16.22 | 16.23 | 15    | 15.82 | 17.69 | 0.7073 | 0.500 | -4.588*   | 0.044 |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.1.1)

**Table-02: Net Profit Margin**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean    | Industry Mean | S.D    | C.V    | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|---------|---------------|--------|--------|-----------|----------------|
| ACTIVEFINE                  | 1.80    | 2.40    | 2.53    | 2.24    | 1.35          | 0.3894 | 0.152  | 3.974     | 0.058          |
| SQURPHARMA                  | 13.31   | 11.13   | 7.83    | 10.75   | 1.35          | 2.7590 | 7.612  | 3.978     | 0.059          |
| IBNSINA                     | 3.87    | 4.67    | 4.78    | 4.44    | 1.35          | 0.4967 | 0.247  | 10.775**  | 0.009          |
| BXPHERMA                    | (4.01)  | (23.30) | (12.79) | (13.36) | 1.35          | 9.6579 | 93.275 | -20.639** | 0.005          |
| RENETA                      | 2.71    | 3.35    | 4.50    | 3.52    | 1.35          | 0.9070 | 0.823  | 4.544*    | 0.050          |
| BEACONPHAR                  | 0.52    | 0.22    | 0.30    | 0.34    | 1.35          | 0.1553 | 0.024  | -11.19**  | 0.008          |
| BEACONPHAR                  | 0.97    | 0.96    | 2.28    | 1.40    | 1.35          | 0.7592 | 0.576  | 0.122     | 0.914          |
| PHARMAID                    | 2.34    | 2.50    | 2.26    | 2.37    | 1.35          | 0.1222 | 0.015  | 14.410**  | 0.005          |
| BPL                         | 0.72    | 0.52    | 0.20    | 0.48    | 1.35          | 0.2623 | 0.069  | -5.624*   | 0.030          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.1.2)

**Table-03: Return on Investment**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean  | Industry Mean | S.D    | C.V    | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|-------|---------------|--------|--------|-----------|----------------|
| ACTIVEFINE                  | 2.57    | 2.93    | 3.09    | 2.86  | 6.67          | 0.2663 | 0.071  | -24.756** | 0.002          |
| SQURPHARMA                  | 20.72   | 32.93   | 19.48   | 24.38 | 6.67          | 7.4333 | 55.254 | 4.126     | 0.054          |
| IBNSINA                     | 11.79   | 15.73   | 15.64   | 14.39 | 6.67          | 2.2492 | 5.059  | 5.942*    | 0.027          |
| BXPHERMA                    | (1.39)  | (6.74)  | (3.19)  | -3.77 | 6.67          | 2.7223 | 7.411  | -6.645*   | 0.022          |
| RENETA                      | 3.69    | 4.79    | 6.20    | 4.89  | 6.67          | 1.2582 | 1.583  | -2.446    | 0.134          |
| BEACONPHAR                  | 4.77    | 2.01    | 2.21    | 3.00  | 6.67          | 1.5390 | 2.369  | -4.134    | 0.054          |
| BEACONPHAR                  | 6.85    | 8.90    | 17.72   | 11.16 | 6.67          | 5.7757 | 33.359 | 1.345     | 0.311          |
| PHARMAID                    | 2.27    | 2.35    | 2.45    | 2.36  | 6.67          | 0.0902 | 0.008  | -82.84**  | 0.000          |
| BPL                         | 0.75    | 0.76    | 0.70    | 0.74  | 6.67          | 0.0321 | 0.001  | -319.69** | 0.000          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.1.3)

**Table-04: Operating Profit Ratio**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean  | Industry Mean | S.D    | C.V    | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|-------|---------------|--------|--------|-----------|----------------|
| ACTIVEFINE                  | 3.92    | 5.27    | 5.32    | 4.84  | 10.72         | 0.7943 | 0.631  | -12.83**  | 0.006          |
| SQURPHARMA                  | 19.63   | 20.89   | 14.78   | 18.43 | 10.72         | 3.2260 | 10.407 | 4.141     | 0.054          |
| IBNSINA                     | 18.09   | 16.47   | 15.18   | 16.58 | 10.72         | 1.4581 | 2.126  | 6.961*    | 0.020          |
| BXPHARMA                    | 29.61   | 23.34   | 34.11   | 29.02 | 10.72         | 5.4092 | 29.259 | 5.860*    | 0.028          |
| RENETA                      | 2.99    | 4.02    | 5.55    | 4.19  | 10.72         | 1.2881 | 1.659  | -8.785*   | 0.013          |
| BEACONPHAR                  | 0.61    | 0.26    | 0.35    | 0.41  | 10.72         | 0.1818 | 0.033  | -98.284** | 0.000          |
| BEACONPHAR                  | 14.10   | 16.01   | 17.87   | 15.99 | 10.72         | 1.8851 | 3.553  | 4.845*    | 0.040          |
| PHARMAID                    | 2.85    | 3.05    | 2.35    | 2.75  | 10.72         | 0.3606 | 0.130  | -38.287** | 0.001          |
| BPL                         | 4.23    | 3.35    | 4.78    | 4.12  | 10.72         | 0.7213 | 0.520  | -15.848** | 0.004          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.1.4)

**Table-05: Return on Capital Employed**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean   | Industry Mean | S.D    | C.V    | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|--------|---------------|--------|--------|-----------|----------------|
| ACTIVEFINE                  | 2.03    | 2.32    | 2.45    | 2.27   | 3.59          | 0.2150 | 0.046  | -10.66**  | 0.009          |
| SQURPHARMA                  | 15.02   | 15.69   | 10.65   | 13.79  | 3.59          | 2.7370 | 7.491  | 6.453*    | 0.023          |
| IBNSINA                     | 3.70    | 5.01    | 5.60    | 4.77   | 3.59          | 0.9725 | 0.946  | 2.102     | 0.170          |
| BXPHARMA                    | (2.32)  | (14.9)  | (5.35)  | (7.52) | 3.59          | 6.5656 | 43.107 | -5.932*   | 0.039          |
| RENETA                      | 0.35    | 3.09    | 4.31    | 2.58   | 3.59          | 2.0280 | 4.113  | -0.860    | 0.481          |
| BEACONPHAR                  | 4.77    | 2.01    | 2.21    | 3.00   | 3.59          | 1.5390 | 2.369  | -0.668    | 0.573          |
| BEACONPHAR                  | 4.06    | 4.92    | 13.62   | 7.53   | 3.59          | 5.2887 | 27.971 | 1.291     | 0.326          |
| PHARMAID                    | 3.70    | 4.33    | 5.21    | 4.41   | 3.59          | 0.7584 | 0.575  | 1.880     | 0.201          |
| BPL                         | 1.53    | 1.59    | 1.25    | 1.46   | 3.59          | 0.1815 | 0.033  | -20.361** | 0.002          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)



(Insert the table after 7.1.5)

**Table-06: Return on Total Assets**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean   | Industry Mean | S.D    | C.V   | t value | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|--------|---------------|--------|-------|---------|----------------|
| ACTIVEFINE                  | 1.61    | 1.88    | 2.01    | 1.83   | 1.83          | 0.2040 | 0.042 | 0.028   | 0.980          |
| SQURPHARMA                  | 9.00    | 8.27    | 5.00    | 7.42   | 1.83          | 2.1302 | 4.538 | 4.548*  | 0.045          |
| IBNSINA                     | 2.31    | 3.11    | 3.20    | 2.87   | 1.83          | 0.4899 | 0.240 | 3.688   | 0.066          |
| BXPHARMA                    | (1.39)  | (6.74)  | (3.19)  | (3.77) | 1.83          | 2.7223 | 7.411 | -3.565  | 0.070          |
| RENETA                      | 2.23    | 3.09    | 4.31    | 3.21   | 1.83          | 1.0452 | 1.092 | 2.287   | 0.149          |
| BEACONPHAR                  | 1.04    | 0.46    | 0.61    | 0.70   | 1.83          | 0.3011 | 0.091 | -6.482* | 0.023          |
| BEACONPHAR                  | 0.82    | 1.02    | 2.00    | 1.28   | 1.83          | 0.6315 | 0.399 | -1.509  | 0.270          |
| PHARMAID                    | 2.12    | 2.26    | 2.45    | 2.28   | 1.83          | 0.1656 | 0.027 | 4.671*  | 0.043          |
| BPL                         | 0.75    | 0.76    | 0.25    | 0.59   | 1.83          | 0.2916 | 0.085 | -7.385* | 0.018          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.1.6)

**Table-07: Current Ratio**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean   | Industry Mean | S.D   | C.V   | t value  | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|--------|---------------|-------|-------|----------|----------------|
| ACTIVEFINE                  | 1.26:1  | 1.51:1  | 1.74:1  | 1.08:1 | 0.94:1        | 0.241 | 0.058 | 4.064    | 0.056          |
| SQURPHARMA                  | 1.05:1  | 1.09:1  | 1.21:1  | 1.12:1 | 0.94:1        | 0.083 | 0.007 | 3.675    | 0.067          |
| IBNSINA                     | 0.98:1  | 1.13:1  | 1.19:1  | 1.10:1 | 0.94:1        | 0.108 | 0.012 | 2.562    | 0.125          |
| BXPHARMA                    | 1.27:1  | 0.98:1  | 0.92:1  | 1.06:1 | 0.94:1        | 0.187 | 0.035 | 1.080    | 0.393          |
| RENETA                      | 1.09:1  | 1.08:1  | 1.06:1  | 1.08:1 | 0.94:1        | 0.015 | 0.001 | 15.497** | 0.004          |
| BEACONPHAR                  | 0.70:1  | 0.60:1  | 0.52:1  | 0.61:1 | 0.94:1        | 0.090 | 0.008 | -6.402*  | 0.024          |
| BEACONPHAR                  | 0.58:1  | 0.56:1  | 0.56:1  | 0.57:1 | 0.94:1        | 0.012 | 0.001 | -56.00** | 0.000          |
| PHARMAID                    | 0.98:1  | 0.97:1  | 0.98:1  | 0.98:1 | 0.94:1        | 0.006 | 0.001 | 11.00**  | 0.008          |
| BPL                         | 0.98:1  | 0.90:1  | 0.67:1  | 0.85:1 | 0.94:1        | 0.161 | 0.026 | -0.969   | 0.435          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.2.1)

**Table-08: Liquid/ Quick/ Acid Test Ratio**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean   | Industry Mean | S.D   | C.V   | t value | Sig.(2 tailed ) |
|-----------------------------|---------|---------|---------|--------|---------------|-------|-------|---------|-----------------|
| ACTIVEFINE                  | 1.06:1  | 1.31:1  | 1.47:1  | 1.28:1 | 0.57:1        | 0.207 | 0.043 | 5.951*  | 0.027           |
| SQURPHARMA                  | 0.58:1  | 0.66:1  | 0.69:1  | 0.64:1 | 0.57:1        | 0.057 | 0.003 | 2.234   | 0.155           |
| IBNSINA                     | 0.35:1  | 0.34:1  | 0.18:1  | 0.29:1 | 0.57:1        | 0.096 | 0.009 | -5.084* | 0.037           |
| BXPHERMA                    | 0.68:1  | 0.52:1  | 0.57:1  | 0.59:1 | 0.57:1        | 0.082 | 0.007 | 0.423   | 0.713           |
| RENETA                      | 0.51:1  | 0.66:1  | 0.49:1  | 0.55:1 | 0.57:1        | 0.093 | 0.009 | -0.311  | 0.783           |
| BEACONPHAR                  | 0.32:1  | 0.23:1  | 0.33:1  | 0.29:1 | 0.57:1        | 0.055 | 0.003 | -8.701* | 0.013           |
| BEACONPHAR                  | 0.42:1  | 0.37:1  | 0.34:1  | 0.38:1 | 0.57:1        | 0.040 | 0.002 | -8.286* | 0.014           |
| PHARMAID                    | 0.59:1  | 0.76:1  | 0.74:1  | 0.70:1 | 0.57:1        | 0.093 | 0.009 | 2.361   | 0.142           |
| BPL                         | 0.47:1  | 0.50:1  | 0.32:1  | 0.43:1 | 0.57:1        | 0.096 | 0.009 | -2.514  | 0.128           |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.2.2)

**STable-09: Current Assets to Fixed Assets**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean   | Industry Mean | S.D   | C.V   | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|--------|---------------|-------|-------|-----------|----------------|
| ACTIVEFINE                  | 0.35:1  | 0.40:1  | 0.46:1  | 0.40:1 | 0.78:1        | 0.055 | 0.003 | -11.846** | 0.007          |
| SQURPHARMA                  | 0.66:1  | 0.96:1  | 1.56:1  | 1.06:1 | 0.78:1        | 0.458 | 0.211 | 1.058     | 0.401          |
| IBNSINA                     | 0.58:1  | 0.74:1  | 1.04:1  | 0.79:1 | 0.78:1        | 0.234 | 0.055 | 0.049     | 0.965          |
| BXPHERMA                    | 1.04:1  | 1.16:1  | 0.61:1  | 0.94:1 | 0.78:1        | 0.289 | 0.084 | 0.938     | 0.447          |
| RENETA                      | 0.44:1  | 0.43:1  | 0.66:1  | 0.51:1 | 0.78:1        | 0.130 | 0.017 | -3.597    | 0.069          |
| BEACONPHAR                  | 1.22:1  | 0.85:1  | 0.60:1  | 0.89:1 | 0.78:1        | 0.312 | 0.098 | 0.611     | 0.604          |
| BEACONPHAR                  | 0.82:1  | 0.90:1  | 1.03:1  | 0.92:1 | 0.78:1        | 0.106 | 0.011 | 2.233     | 0.155          |
| PHARMAID                    | 0.79:1  | 0.90:1  | 1.09:1  | 0.93:1 | 0.78:1        | 0.152 | 0.023 | 1.674     | 0.236          |
| BPL                         | 0.50:1  | 0.74:1  | 0.60:1  | 0.61:1 | 0.78:1        | 0.121 | 0.015 | -2.395    | 0.139          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.2.3)

**Table-10: Net Working Capital to Total Assets**

| Name of the Pharmaceuticals | 2005-06  | 2006-07  | 2007-08  | Mean     | Industry Mean | S.D    | C.V   | t value  | Sig.(2 tailed) |
|-----------------------------|----------|----------|----------|----------|---------------|--------|-------|----------|----------------|
| ACTIVEFINE                  | (0.005)  | 0.04     | 0.08     | 0.0383   | (0.0099)      | 0.0425 | 0.002 | 1.965    | 0.188          |
| SQURPHARMA                  | 0.019    | 0.04     | 0.104    | 0.0543   | (0.0099)      | 0.0443 | 0.002 | 2.513    | 0.129          |
| IBNSINA                     | (0.006)  | 0.047    | 0.080    | 0.0403   | (0.0099)      | 0.0434 | 0.002 | 2.006    | 0.183          |
| BXPHERMA                    | 0.018    | (0.012)  | (0.035)  | 0.0203   | (0.0099)      | 0.0266 | 0.001 | 0.020    | 0.986          |
| RENETA                      | 0.026    | 0.024    | 0.024    | 0.0247   | (0.0099)      | 0.0012 | 0.000 | 54.684** | 0.000          |
| BEACONPHAR                  | (0.233)  | (0.307)  | (0.348)  | (0.2960) | (0.0099)      | 0.0583 | 0.003 | -8.508*  | 0.014          |
| BEACONPHAR                  | (0.0003) | (0.0004) | (0.0004) | (0.0004) | (0.0099)      | 0.0001 | 0.000 | 4.465*   | 0.050          |
| PHARMAID                    | (0.008)  | (0.0140) | (0.0122) | (0.0114) | (0.0099)      | 0.0031 | 0.000 | -0.821   | 0.498          |
| BPL                         | (0.008)  | (0.05)   | 0.18     | 0.0407   | (0.0099)      | 0.1225 | 0.015 | 0.716    | 0.548          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.2.4)

**Table-11: Inventory Turnover**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean  | Industry Mean | S.D    | C.V    | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|-------|---------------|--------|--------|-----------|----------------|
| ACTIVEFINE                  | 22.30   | 21.00   | 16.67   | 19.99 | 6.45          | 2.9478 | 8.689  | 7.956*    | 0.015          |
| SQURPHARMA                  | 4.09    | 4.26    | 2.76    | 3.70  | 6.45          | 0.8214 | 0.675  | -5.792*   | 0.029          |
| IBNSINA                     | 1.66    | 2.09    | 1.56    | 1.77  | 6.45          | 0.2816 | 0.079  | -28.785** | 0.001          |
| BXPHERMA                    | 1.52    | 1.16    | 1.74    | 1.47  | 6.45          | 0.2928 | 0.086  | -29.439** | 0.001          |
| RENETA                      | 3.64    | 5.64    | 2.79    | 4.03  | 6.45          | 1.4632 | 2.141  | -2.873    | 0.103          |
| BEACONPHAR                  | 6.75    | 7.45    | 14.36   | 9.52  | 6.45          | 4.2062 | 17.692 | 1.264     | 0.334          |
| BEACONPHAR                  | 3.82    | 5.70    | 4.14    | 4.55  | 6.45          | 1.0058 | 1.012  | -3.266    | 0.082          |
| PHARMAID                    | 5.44    | 8.81    | 10.15   | 8.13  | 6.45          | 2.4268 | 5.889  | 1.201     | 0.353          |
| BPL                         | 3.35    | 5.67    | 5.55    | 4.86  | 6.45          | 1.3062 | 1.706  | -2.113    | 0.169          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.3.1)

**Table-12: Net Fixed Assets Turnover**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean | Industry Mean | S.D    | C.V   | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|------|---------------|--------|-------|-----------|----------------|
| ACTIVEFINE                  | 1.22    | 1.12    | 1.17    | 1.17 | 1.67          | 0.0500 | 0.003 | -17.321** | 0.003          |
| SQURPHARMA                  | 1.13    | 1.45    | 1.64    | 1.41 | 1.67          | 0.2577 | 0.066 | -1.770    | 0.219          |
| IBNSINA                     | 0.95    | 1.16    | 1.36    | 1.16 | 1.67          | 0.2050 | 0.042 | -4.337*   | 0.049          |
| BXPHARMA                    | 0.71    | 0.63    | 0.40    | 0.58 | 1.67          | 0.1609 | 0.026 | -11.731** | 0.007          |
| RENETA                      | 0.86    | 0.96    | 1.00    | 0.94 | 1.67          | 0.0721 | 0.005 | -17.534** | 0.003          |
| BEACONPHAR                  | 4.43    | 3.96    | 3.23    | 3.87 | 1.67          | 0.6047 | 0.366 | 6.311*    | 0.024          |
| BEACONPHAR                  | 1.29    | 1.56    | 1.51    | 1.45 | 1.67          | 0.1436 | 0.021 | -2.613    | 0.121          |
| PHARMAID                    | 1.72    | 1.71    | 2.63    | 2.02 | 1.67          | 0.5283 | 0.279 | 1.147     | 0.370          |
| BPL                         | 2.34    | 2.87    | 2.03    | 4.41 | 1.67          | 0.4248 | 0.180 | 3.031     | 0.094          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.3.2)

**Table-13: Total Assets Turnover**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean | Industry Mean | S.D    | C.V   | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|------|---------------|--------|-------|-----------|----------------|
| ACTIVEFINE                  | 0.89    | 0.76    | 0.79    | 0.81 | 0.90          | 0.0681 | 0.005 | -2.205    | 0.158          |
| SQURPHARMA                  | 0.68    | 0.74    | 0.64    | 0.69 | 0.90          | 0.0503 | 0.003 | -7.341*   | 0.018          |
| IBNSINA                     | 0.60    | 0.67    | 0.67    | 0.65 | 0.90          | 0.0404 | 0.002 | -10.857** | 0.008          |
| BXPHARMA                    | 0.35    | 0.29    | 0.25    | 0.30 | 0.90          | 0.0503 | 0.003 | -20.762** | 0.002          |
| RENETA                      | 0.59    | 0.67    | 0.60    | 0.62 | 0.90          | 0.0436 | 0.002 | -11.126** | 0.008          |
| BEACONPHAR                  | 1.99    | 2.13    | 2.00    | 2.04 | 0.90          | 0.0781 | 0.006 | 25.281**  | 0.002          |
| BEACONPHAR                  | 0.72    | 0.84    | 0.74    | 0.77 | 0.90          | 0.0643 | 0.004 | -3.592    | 0.070          |
| PHARMAID                    | 0.90    | 0.87    | 1.23    | 1.00 | 0.90          | 0.1997 | 0.040 | 0.867     | 0.477          |
| BPL                         | 1.04    | 1.40    | 1.27    | 1.24 | 0.90          | 0.1823 | 0.033 | 3.199     | 0.085          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.3.3)

**Table-14: Debt-Equity Ratio**

| Name of the | 2005-06 | 2006-07 | 2007-08 | Mean | Industry | S.D | C.V | t value | Sig.(2 |
|-------------|---------|---------|---------|------|----------|-----|-----|---------|--------|
|-------------|---------|---------|---------|------|----------|-----|-----|---------|--------|

| Pharmaceuticals |      |      |      |      | Mean |       |       |            | tailed) |
|-----------------|------|------|------|------|------|-------|-------|------------|---------|
| ACTIVEFINE      | 0.35 | 0.32 | 0.31 | 0.33 | 2.01 | 0.021 | 0.001 | -140.062** | 0.000   |
| SQURPHARMA      | 1.14 | 1.18 | 0.92 | 1.08 | 2.01 | 0.140 | 0.019 | -11.506**  | 0.007   |
| IBNSINA         | 0.60 | 0.61 | 0.75 | 0.65 | 2.01 | 0.084 | 0.007 | -28.019**  | 0.001   |
| BXPCHARMA       | 2.03 | 2.45 | 2.33 | 2.27 | 2.01 | 0.216 | 0.047 | 2.082      | 0.173   |
| RENETA          | 1.29 | 1.14 | 1.29 | 1.24 | 2.01 | 0.087 | 0.008 | -15.400**  | 0.004   |
| BEACONPHAR      | 3.59 | 3.33 | 2.64 | 3.19 | 2.01 | 0.491 | 0.241 | 4.151*     | 0.053   |
| BEACONPHAR      | 6.97 | 7.44 | 7.28 | 7.23 | 2.01 | 0.239 | 0.057 | 37.837**   | 0.001   |
| PHARMAID        | 2.21 | 2.48 | 2.71 | 2.44 | 2.01 | 0.251 | 0.063 | 3.161      | 0.087   |
| BPL             | 0.39 | 0.58 | 0.98 | 0.65 | 2.01 | 0.301 | 0.091 | -7.822*    | 0.016   |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.4.1)

**Table-15: Debt to Total Assets Ratio**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean | Industry Mean | S.D    | C.V   | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|------|---------------|--------|-------|-----------|----------------|
| ACTIVEFINE                  | 0.08    | 0.07    | 0.06    | 0.07 | 0.36          | 0.0100 | 0.000 | 50.229**  | 0.000          |
| SQURPHARMA                  | 0.30    | 0.31    | 0.24    | 0.28 | 0.36          | 0.0379 | 0.001 | -3.507    | 0.073          |
| IBNSINA                     | 0.35    | 0.36    | 0.34    | 0.35 | 0.36          | 0.0100 | 0.000 | -1.732    | 0.225          |
| BXPCHARMA                   | 0.74    | 0.76    | 0.74    | 0.75 | 0.36          | 0.0115 | 0.000 | 58.00**   | 0.000          |
| RENETA                      | 0.36    | 0.33    | 0.30    | 0.33 | 0.36          | 0.0300 | 0.001 | -1.732    | 0.225          |
| BEACONPHAR                  | 0.20    | 0.25    | 0.27    | 0.24 | 0.36          | 0.0361 | 0.001 | -5.765*   | 0.029          |
| BEACONPHAR                  | 0.82    | 0.83    | 0.83    | 0.83 | 0.36          | 0.0058 | 0.000 | 140.00**  | 0.000          |
| PHARMAID                    | 0.30    | 0.27    | 0.24    | 0.27 | 0.36          | 0.0300 | 0.001 | -5.196*   | 0.035          |
| BPL                         | 0.13    | 0.17    | 0.10    | 0.13 | 0.36          | 0.0351 | 0.001 | -11.179** | 0.008          |

Source: Annual Report and Official Records of the selected Pharmaceuticals

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 7.4.2)



**Table: 16 (Ratios for Testing Financial Soundness)**

| Ratios                                                  | ACTI<br>VEFIN<br>E | SQU<br>RPH<br>ARM<br>A | IBNS<br>INA | BXPH<br>ARM<br>A | RENET<br>A | BEACO<br>NPHAR | AMBEEP<br>HA<br>BEACONP<br>HAR | PHARMA<br>ID | BPL     | Year    |
|---------------------------------------------------------|--------------------|------------------------|-------------|------------------|------------|----------------|--------------------------------|--------------|---------|---------|
| Working<br>Capital to<br>Total<br>Assets (in<br>time)   | (0.005)            | 0.019                  | (0.007)     | 0.108            | 0.026      | (0.233)        | (0.0003)                       | (0.008)      | (0.008) | 2005-06 |
|                                                         | 0.040              | 0.401                  | 0.047       | (0.012)          | 0.024      | (0.307)        | (0.0004)                       | (0.014)      | (0.05)  | 2006-07 |
|                                                         | 0.080              | 0.104                  | 0.080       | (0.035)          | 0.024      | (0.348)        | (0.0004)                       | (0.012)      | (0.18)  | 207-08  |
|                                                         | 0.038              | 0.174                  | 0.04        | 0.021            | 0.025      | (0.296)        | (0.0004)                       | (0.012)      | (0.079) | Mean    |
|                                                         | 0.042              | 0.200                  | 0.044       | 0.077            | 0.001      | 0.0583         | 0.00001                        | 0.0031       | 0.0897  | S. D.   |
|                                                         | 0.002              | 0.040                  | 0.002       | 0.006            | 0.000      | 0.0034         | 0.00000                        | 0.0000       | 0.0081  | C. V.   |
| Retained<br>Earnings to<br>Total<br>Assets (in<br>time) | 0.007              | 0.09                   | 0.016       | (0.014)          | (0.039)    | (0.314)        | 0.0067                         | 0.0028       | 0.008   | 2005-06 |
|                                                         | 0.012              | 0.083                  | 0.001       | (0.067)          | (0.036)    | (0.329)        | 0.0079                         | 0.0052       | 0.006   | 2006-07 |
|                                                         | 0.017              | 0.050                  | 0.003       | (0.032)          | (0.022)    | (0.390)        | 0.0164                         | 0.0056       | 0.002   | 207-08  |
|                                                         | 0.012              | 0.074                  | 0.007       | (0.037)          | (0.032)    | (0.344)        | 0.0103                         | 0.0045       | 0.005   | Mean    |
|                                                         | 0.005              | 0.021                  | 0.008       | 0.027            | 0.009      | 0.041          | 0.0053                         | 0.0015       | 0.003   | S. D.   |
|                                                         | 0.000              | 0.001                  | 0.000       | 0.001            | 0.000      | 0.002          | 0.0000                         | 0.0000       | 0.000   | C. V.   |
| Earning<br>before<br>interest and<br>taxes to           | 0.019              | 0.124                  | 0.078       | 0.077            | 0.37       | 0.048          | 0.099                          | 0.046        | 0.030   | 2005-06 |
|                                                         | 0.022              | 0.129                  | 0.103       | 0.024            | 0.047      | 0.050          | 0.132                          | 0.067        | 0.034   | 2006-07 |
|                                                         | 0.024              | 0.092                  | 0.095       | 0.036            | 0.051      | 0.057          | 0.137                          | 0.064        | 0.008   | 207-08  |

|                                                |                                                  |                                                 |                                                 |                                                 |                                                 |                                                |                                                    |                                                    |                                                 |                                                        |
|------------------------------------------------|--------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------|--------------------------------------------------------|
| Total Assets (in time)                         | 0.022<br>0.003<br>0.000                          | 0.115<br>0.020<br>0.001                         | 0.092<br>0.013<br>0.000                         | 0.045<br>0.028<br>0.001                         | 0.156<br>0.185<br>0.342                         | 0.052<br>0.005<br>0.000                        | 0.123<br>0.021<br>0.001                            | 0.059<br>0.011<br>0.000                            | 0.024<br>0.014<br>0.000                         | Mean<br>S. D.<br>C. V.                                 |
| Market value of equity to Total Debt (in time) | 2.86<br>3.125<br>3.23<br>3.072<br>0.191<br>0.037 | 0.88<br>0.85<br>1.09<br>0.94<br>0.131<br>0.017  | 1.67<br>1.64<br>1.33<br>1.547<br>0.188<br>0.035 | 0.49<br>0.41<br>0.43<br>0.443<br>0.042<br>0.002 | 0.78<br>0.88<br>0.78<br>0.813<br>0.058<br>0.003 | 0.28<br>0.30<br>0.38<br>0.32<br>0.053<br>0.003 | 0.143<br>0.134<br>0.137<br>0.138<br>0.005<br>0.000 | 0.471<br>0.403<br>0.369<br>0.414<br>0.052<br>0.003 | 2.56<br>1.72<br>1.02<br>1.767<br>0.771<br>0.594 | 2005-06<br>2006-07<br>207-08<br>Mean<br>S. D.<br>C. V. |
| Sales to Total Asset (in time)                 | 0.89<br>0.76<br>0.79<br>0.813<br>0.068<br>0.005  | 0.68<br>0.74<br>0.64<br>0.687<br>0.050<br>0.003 | 0.59<br>0.68<br>0.67<br>0.647<br>0.049<br>0.002 | 0.35<br>0.29<br>0.25<br>0.297<br>0.050<br>0.003 | 0.59<br>0.67<br>0.60<br>0.62<br>0.043<br>0.002  | 1.99<br>2.13<br>2.00<br>2.04<br>0.078<br>0.006 | 0.709<br>0.819<br>0.721<br>0.749<br>0.060<br>0.004 | 0.90<br>0.87<br>1.23<br>1.00<br>0.199<br>0.040     | 1.04<br>1.40<br>1.24<br>1.227<br>0.180<br>0.032 | 2005-06<br>2006-07<br>207-08<br>Mean<br>S. D.<br>C. V. |

Source: Annual Report and Official Records of the selected Pharmaceuticals industry, (2005-2008)

(Insert the table after 8)

**Table: 17 (Analysis of Z score)**

| Name of the Pharmaceuticals | 2005-06 | 2006-07 | 2007-08 | Mean  | Industry Mean | S.D   | C.V   | t value   | Sig.(2 tailed) |
|-----------------------------|---------|---------|---------|-------|---------------|-------|-------|-----------|----------------|
| ACTIVEFINE                  | 0.907   | 0.779   | 0.810   | 0.832 | 0.909         | 0.067 | 0.005 | -1.997    | 0.184          |
| SQURPHARMA                  | 0.690   | 0.754   | 0.761   | 0.735 | 0.909         | 0.039 | 0.002 | -7.702*   | 0.016          |
| IBNSINA                     | 0.602   | 0.683   | 0.680   | 0.655 | 0.909         | 0.046 | 0.002 | -9.580*   | 0.011          |
| BXPCHARMA                   | 0.354   | 0.290   | 0.251   | 0.298 | 0.909         | 0.052 | 0.003 | -20.789** | 0.002          |
| RENETA                      | 0.606   | 0.676   | 0.610   | 0.633 | 0.909         | 0.039 | 0.002 | -12.264** | 0.007          |
| BEACONPHAR                  | 1.986   | 2.122   | 1.992   | 2.033 | 0.909         | 0.077 | 0.006 | 25.342**  | 0.002          |
| BEACONPHAR                  | 0.713   | 0.823   | 0.726   | 0.754 | 0.909         | 0.060 | 0.004 | -4.466*   | 0.047          |
| PHARMAID                    | 0.903   | 0.876   | 1.233   | 1.004 | 0.909         | 0.199 | 0.039 | 0.828     | 0.495          |
| BPL                         | 1.065   | 1.414   | 1.240   | 1.243 | 0.909         | 0.175 | 0.031 | 3.282     | 0.082          |

\*Significant at the 0.05 level (2-tailed). \*\* Significant at the 0.01 level (2-tailed)

(Insert the table after 8 with table-16)

**Table: 18 List of Pharmaceuticals under study:**

|                                |                 |
|--------------------------------|-----------------|
| Name of the Pharmaceuticals    | Short name used |
| Active Fine Chemicals Limited  | ACTIVEFINE      |
| Square Pharmaceuticals Limited | SQURPHARMA      |

|                                   |            |
|-----------------------------------|------------|
| The Ibn Sina Pharmaceuticals Ltd. | IBNSINA    |
| Beximco Pharma                    | BXPHARMA   |
| Renata Ltd.                       | RENATA     |
| Beasel Pharmaceuticals Limited    | BEACONPHAR |
| Ambee Pharma                      | AMBEEPHA   |
| Pharma Aids                       | PHARMAID   |
| Beacon Pharmaceuticals Limited    | BPL        |

(Insert the table after references)

This academic article was published by The International Institute for Science, Technology and Education (IISTE). The IISTE is a pioneer in the Open Access Publishing service based in the U.S. and Europe. The aim of the institute is Accelerating Global Knowledge Sharing.

More information about the publisher can be found in the IISTE's homepage:

<http://www.iiste.org>

The IISTE is currently hosting more than 30 peer-reviewed academic journals and collaborating with academic institutions around the world. **Prospective authors of IISTE journals can find the submission instruction on the following page:**

<http://www.iiste.org/Journals/>

The IISTE editorial team promises to review and publish all the qualified submissions in a fast manner. All the journals articles are available online to the readers all over the world without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. Printed version of the journals is also available upon request of readers and authors.

### **IISTE Knowledge Sharing Partners**

EBSCO, Index Copernicus, Ulrich's Periodicals Directory, JournalTOCS, PKP Open Archives Harvester, Bielefeld Academic Search Engine, Elektronische Zeitschriftenbibliothek EZB, Open J-Gate, OCLC WorldCat, Universe Digital Library, NewJour, Google Scholar

